DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Cardene SR (Nicardipine Hydrochloride) - Summary



CARDENE® SR is a sustained release formulation of CARDENE®. CARDENE SR capsules for oral administration each contain 30 mg, 45 mg or 60 mg of nicardipine hydrochloride. Nicardipine hydrochloride is a calcium ion influx inhibitor (slow channel blocker or calcium entry blocker).

CARDENE SR is indicated for the treatment of hypertension. CARDENE SR may be used alone or in combination with other antihypertensive drugs.

See all Cardene SR indications & dosage >>


Media Articles Related to Cardene SR (Nicardipine)

A General Cardiologist's Approach to Managing Hypertension
Source: theheart.org | Medscape Cardiology Headlines [2015.11.23]
Dr Henry Black interviews Dr John Bisognano and discusses his approach to managing hypertension and treating resistant hypertension.
Medscape Cardiology

International Conference on Hypertension & Treatment, August 04-06, 2016, Toronto
Source: Conferences News From Medical News Today [2015.11.13]
OMICS International announces the International Conference on Hypertension & Treatment to be held during August 04-06, 2016 at Toronto, Canada, focusing on "Hypertension and Treatment" with a view...

White coat and masked hypertension associated with higher rates of heart and vascular disease
Source: Hypertension News From Medical News Today [2015.11.10]
Patients whose blood pressures spikes in the doctor's office but not at home, and patients whose blood pressure spikes at home but not in the doctor's office, suffer more heart attacks, heart...

Efforts needed to improve the diets of African-Americans with uncontrolled hypertension
Source: Hypertension News From Medical News Today [2015.11.09]
Many African Americans with uncontrolled hypertension do not have recommended food categories in their homes and are not having adequate discussions with their doctors about diet.

New studies focus on hypertension in pregnant women and children
Source: Hypertension News From Medical News Today [2015.11.09]
Research is revealing new insights related to hypertension in pregnant women and children.

more news >>

Published Studies Related to Cardene SR (Nicardipine)

Development of nicardipine prolonged-release implants after clipping for preventing cerebral vasospasm: from laboratory to clinical trial. [2013]
We have developed a drug delivery system using a vasodilating drug that can be implanted intracranially at the time of surgery for aneurysm clipping, without systemic side effects or side effects associated with long-term intrathecal drug administration.We have performed three studies (a single-center study with consecutive patients; a single-center, randomized, double-blind trial; and a multicenter cooperative study) and have proved that implantation of NPRIs reduces the incidence of cerebral vasospasm and DINDs and improves clinical outcome after SAH.

CLUE: a randomized comparative effectiveness trial of IV nicardipine versus labetalol use in the emergency department. [2011]
INTRODUCTION: Our purpose was to compare the safety and efficacy of food and drug administration (FDA) recommended dosing of IV nicardipine versus IV labetalol for the management of acute hypertension... CONCLUSIONS: Patients treated with nicardipine are more likely to reach the physician-specified SBP target range within 30 minutes than those treated with labetalol.

Nicardipine vs. saline injection as treatment for Peyronie's disease: a prospective, randomized, single-blind trial. [2010.11]
INTRODUCTION: Various conservative treatments for Peyronie's disease (PD) have been attempted over the years. Intralesional verapamil injection has been tested in prospective randomized studies, but the effect of this treatment seems insufficient. Nicardipine is a calcium antagonist alternative to verapamil and is reportedly more effective in vitro. AIM: The objective of our study was to evaluate the usefulness of intralesional nicardipine injection as a conservative treatment for PD in the transition period of acute and chronic phase... CONCLUSION: Our findings indicate that intralesional nicardipine injection is clinically effective as a conservative treatment for PD in the transition period of acute and chronic phase. (c) 2010 International Society for Sexual Medicine.

Effect of intracoronary nicardipine on cardiac enzymes after elective percutaneous coronary intervention. [2009.06]
BACKGROUND: Elevation in cardiac enzymes after percutaneous coronary intervention (PCI) is common and is associated with adverse clinical outcomes. HYPOTHESIS: Administration of intracoronary nicardipine-a calcium channel blocker will reduce cardiac enzyme levels in patients undergoing elective PCI... CONCLUSIONS: In low-risk patients undergoing elective PCI, intracoronary nicardipine administration did not produce a significant cardioprotective effect in reducing postprocedural cardiac enzymes leakage. Copyright (c) 2009 Wiley Periodicals, Inc.

Effect of nicardipine on renal function after robot-assisted laparoscopic radical prostatectomy. [2009.05]
OBJECTIVES: To investigate the renoprotective effect of nicardipine in patients undergoing robot-assisted laparoscopic radical prostatectomy (RALRP) in a prospective trial. Superior visualization of the increasingly performed RALRP requires pneumoperitoneum and extreme head-down tilt, both of which are associated with a decrease in postoperative renal function. Nicardipine causes preferential dilation of the renal arterioles and attenuates renal dysfunction after cardiac surgery... CONCLUSIONS: Continuous infusion of low-dose nicardipine during RALRP seems to offset the deleterious effects of inevitable pneumoperitoneum and extreme head-down tilt on renal function in preserving the eGFR and attenuating the development of renal insufficiency in the immediate postoperative period.

more studies >>

Clinical Trials Related to Cardene SR (Nicardipine)

A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of Cardene® I.V. in Pediatric Subjects With Hypertension [Withdrawn]
To define the relationship between Cardene I. V. dose, serum concentrations, and blood pressure reduction in pediatric subjects with hypertension.

Safety Study of Nicardipine to Treat Cerebral Vasospasm [Terminated]

Evaluation of Intravenous Cardene(Nicardipine)and Labetalol Use in the Emergency Department [Completed]

Effect of Nicardipine on Renal Function in Deliberate Hypotension [Completed]
The aim of this study was to demonstrate the effect of nicardipine on renal function with creatinine clearance, serum cystatin C, urine output and fractional excretion of sodium during deliberate hypotension for spine surgery.

IV Double and Triple Concentrated Nicardipine for Stroke and ICH [Recruiting]
Hypertension (high blood pressure) can often cause neurological worsening in patients with stroke, intracerebral hemorrhage and subarachnoid hemorrhage. Intravenous infusion of nicardipine (Cardene) for control of hypertension is FDA approved. The disadvantage of Nicardipine IV drip is the relative large volume of fluid needed (up to 150 cc/hr). The purpose of this study is to evaluate safety and efficacy of double or triple concentrated peripheral intravenous (IV) Nicardipine.

more trials >>

Page last updated: 2015-11-23

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015